- IBDEI03Q ; ; 01-AUG-2022
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,8942,1,4,0)
- ;;=4^D63.0
- ;;^UTILITY(U,$J,358.3,8942,2)
- ;;=^321978
- ;;^UTILITY(U,$J,358.3,8943,0)
- ;;=D63.8^^45^431^22
- ;;^UTILITY(U,$J,358.3,8943,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8943,1,3,0)
- ;;=3^Anemia in Chronic Diseases Classified Elsewhere
- ;;^UTILITY(U,$J,358.3,8943,1,4,0)
- ;;=4^D63.8
- ;;^UTILITY(U,$J,358.3,8943,2)
- ;;=^5002343
- ;;^UTILITY(U,$J,358.3,8944,0)
- ;;=C22.3^^45^431^27
- ;;^UTILITY(U,$J,358.3,8944,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8944,1,3,0)
- ;;=3^Angiosarcoma of Liver
- ;;^UTILITY(U,$J,358.3,8944,1,4,0)
- ;;=4^C22.3
- ;;^UTILITY(U,$J,358.3,8944,2)
- ;;=^5000936
- ;;^UTILITY(U,$J,358.3,8945,0)
- ;;=D61.9^^45^431^28
- ;;^UTILITY(U,$J,358.3,8945,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8945,1,3,0)
- ;;=3^Aplastic Anemia,Unspec
- ;;^UTILITY(U,$J,358.3,8945,1,4,0)
- ;;=4^D61.9
- ;;^UTILITY(U,$J,358.3,8945,2)
- ;;=^5002342
- ;;^UTILITY(U,$J,358.3,8946,0)
- ;;=D56.1^^45^431^34
- ;;^UTILITY(U,$J,358.3,8946,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8946,1,3,0)
- ;;=3^Beta Thalassemia
- ;;^UTILITY(U,$J,358.3,8946,1,4,0)
- ;;=4^D56.1
- ;;^UTILITY(U,$J,358.3,8946,2)
- ;;=^340495
- ;;^UTILITY(U,$J,358.3,8947,0)
- ;;=C83.79^^45^431^36
- ;;^UTILITY(U,$J,358.3,8947,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8947,1,3,0)
- ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,8947,1,4,0)
- ;;=4^C83.79
- ;;^UTILITY(U,$J,358.3,8947,2)
- ;;=^5001600
- ;;^UTILITY(U,$J,358.3,8948,0)
- ;;=C83.70^^45^431^37
- ;;^UTILITY(U,$J,358.3,8948,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8948,1,3,0)
- ;;=3^Burkitt Lymphoma,Unspec Site
- ;;^UTILITY(U,$J,358.3,8948,1,4,0)
- ;;=4^C83.70
- ;;^UTILITY(U,$J,358.3,8948,2)
- ;;=^5001591
- ;;^UTILITY(U,$J,358.3,8949,0)
- ;;=D09.0^^45^431^44
- ;;^UTILITY(U,$J,358.3,8949,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8949,1,3,0)
- ;;=3^Carcinoma in Situ of Bladder
- ;;^UTILITY(U,$J,358.3,8949,1,4,0)
- ;;=4^D09.0
- ;;^UTILITY(U,$J,358.3,8949,2)
- ;;=^267742
- ;;^UTILITY(U,$J,358.3,8950,0)
- ;;=D06.9^^45^431^45
- ;;^UTILITY(U,$J,358.3,8950,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8950,1,3,0)
- ;;=3^Carcinoma in Situ of Cervix
- ;;^UTILITY(U,$J,358.3,8950,1,4,0)
- ;;=4^D06.9
- ;;^UTILITY(U,$J,358.3,8950,2)
- ;;=^5001941
- ;;^UTILITY(U,$J,358.3,8951,0)
- ;;=D06.0^^45^431^47
- ;;^UTILITY(U,$J,358.3,8951,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8951,1,3,0)
- ;;=3^Carcinoma in Situ of Endocervix
- ;;^UTILITY(U,$J,358.3,8951,1,4,0)
- ;;=4^D06.0
- ;;^UTILITY(U,$J,358.3,8951,2)
- ;;=^5001938
- ;;^UTILITY(U,$J,358.3,8952,0)
- ;;=D06.1^^45^431^48
- ;;^UTILITY(U,$J,358.3,8952,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8952,1,3,0)
- ;;=3^Carcinoma in Situ of Exocervix
- ;;^UTILITY(U,$J,358.3,8952,1,4,0)
- ;;=4^D06.1
- ;;^UTILITY(U,$J,358.3,8952,2)
- ;;=^5001939
- ;;^UTILITY(U,$J,358.3,8953,0)
- ;;=D06.7^^45^431^46
- ;;^UTILITY(U,$J,358.3,8953,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8953,1,3,0)
- ;;=3^Carcinoma in Situ of Cervix,Other Parts
- ;;^UTILITY(U,$J,358.3,8953,1,4,0)
- ;;=4^D06.7
- ;;^UTILITY(U,$J,358.3,8953,2)
- ;;=^5001940
- ;;^UTILITY(U,$J,358.3,8954,0)
- ;;=D04.9^^45^431^49
- ;;^UTILITY(U,$J,358.3,8954,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8954,1,3,0)
- ;;=3^Carcinoma in Situ of Skin
- ;;^UTILITY(U,$J,358.3,8954,1,4,0)
- ;;=4^D04.9
- ;;^UTILITY(U,$J,358.3,8954,2)
- ;;=^5001925
- ;;^UTILITY(U,$J,358.3,8955,0)
- ;;=C91.11^^45^431^52
- ;;^UTILITY(U,$J,358.3,8955,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8955,1,3,0)
- ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
- ;;^UTILITY(U,$J,358.3,8955,1,4,0)
- ;;=4^C91.11
- ;;^UTILITY(U,$J,358.3,8955,2)
- ;;=^5001766
- ;;^UTILITY(U,$J,358.3,8956,0)
- ;;=C91.10^^45^431^53
- ;;^UTILITY(U,$J,358.3,8956,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8956,1,3,0)
- ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
- ;;^UTILITY(U,$J,358.3,8956,1,4,0)
- ;;=4^C91.10
- ;;^UTILITY(U,$J,358.3,8956,2)
- ;;=^5001765
- ;;^UTILITY(U,$J,358.3,8957,0)
- ;;=C92.11^^45^431^54
- ;;^UTILITY(U,$J,358.3,8957,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8957,1,3,0)
- ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
- ;;^UTILITY(U,$J,358.3,8957,1,4,0)
- ;;=4^C92.11
- ;;^UTILITY(U,$J,358.3,8957,2)
- ;;=^5001793
- ;;^UTILITY(U,$J,358.3,8958,0)
- ;;=C92.10^^45^431^55
- ;;^UTILITY(U,$J,358.3,8958,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8958,1,3,0)
- ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
- ;;^UTILITY(U,$J,358.3,8958,1,4,0)
- ;;=4^C92.10
- ;;^UTILITY(U,$J,358.3,8958,2)
- ;;=^5001792
- ;;^UTILITY(U,$J,358.3,8959,0)
- ;;=D47.1^^45^431^56
- ;;^UTILITY(U,$J,358.3,8959,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8959,1,3,0)
- ;;=3^Chronic Myeloproliferative Disease
- ;;^UTILITY(U,$J,358.3,8959,1,4,0)
- ;;=4^D47.1
- ;;^UTILITY(U,$J,358.3,8959,2)
- ;;=^5002256
- ;;^UTILITY(U,$J,358.3,8960,0)
- ;;=C82.69^^45^431^57
- ;;^UTILITY(U,$J,358.3,8960,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8960,1,3,0)
- ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,8960,1,4,0)
- ;;=4^C82.69
- ;;^UTILITY(U,$J,358.3,8960,2)
- ;;=^5001530
- ;;^UTILITY(U,$J,358.3,8961,0)
- ;;=C82.60^^45^431^58
- ;;^UTILITY(U,$J,358.3,8961,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8961,1,3,0)
- ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
- ;;^UTILITY(U,$J,358.3,8961,1,4,0)
- ;;=4^C82.60
- ;;^UTILITY(U,$J,358.3,8961,2)
- ;;=^5001521
- ;;^UTILITY(U,$J,358.3,8962,0)
- ;;=D56.2^^45^431^59
- ;;^UTILITY(U,$J,358.3,8962,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8962,1,3,0)
- ;;=3^Delta-Beta Thalassemia
- ;;^UTILITY(U,$J,358.3,8962,1,4,0)
- ;;=4^D56.2
- ;;^UTILITY(U,$J,358.3,8962,2)
- ;;=^340496
- ;;^UTILITY(U,$J,358.3,8963,0)
- ;;=D75.9^^45^431^60
- ;;^UTILITY(U,$J,358.3,8963,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8963,1,3,0)
- ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
- ;;^UTILITY(U,$J,358.3,8963,1,4,0)
- ;;=4^D75.9
- ;;^UTILITY(U,$J,358.3,8963,2)
- ;;=^5002393
- ;;^UTILITY(U,$J,358.3,8964,0)
- ;;=D59.0^^45^431^63
- ;;^UTILITY(U,$J,358.3,8964,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8964,1,3,0)
- ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
- ;;^UTILITY(U,$J,358.3,8964,1,4,0)
- ;;=4^D59.0
- ;;^UTILITY(U,$J,358.3,8964,2)
- ;;=^5002323
- ;;^UTILITY(U,$J,358.3,8965,0)
- ;;=D59.2^^45^431^64
- ;;^UTILITY(U,$J,358.3,8965,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8965,1,3,0)
- ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
- ;;^UTILITY(U,$J,358.3,8965,1,4,0)
- ;;=4^D59.2
- ;;^UTILITY(U,$J,358.3,8965,2)
- ;;=^5002325
- ;;^UTILITY(U,$J,358.3,8966,0)
- ;;=R59.9^^45^431^67
- ;;^UTILITY(U,$J,358.3,8966,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8966,1,3,0)
- ;;=3^Enlarged Lymph Nodes,Unspec
- ;;^UTILITY(U,$J,358.3,8966,1,4,0)
- ;;=4^R59.9
- ;;^UTILITY(U,$J,358.3,8966,2)
- ;;=^5019531
- ;;^UTILITY(U,$J,358.3,8967,0)
- ;;=D47.3^^45^431^68
- ;;^UTILITY(U,$J,358.3,8967,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8967,1,3,0)
- ;;=3^Essential Thrombocythemia
- ;;^UTILITY(U,$J,358.3,8967,1,4,0)
- ;;=4^D47.3
- ;;^UTILITY(U,$J,358.3,8967,2)
- ;;=^5002258
- ;;^UTILITY(U,$J,358.3,8968,0)
- ;;=C82.09^^45^431^69
- ;;^UTILITY(U,$J,358.3,8968,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8968,1,3,0)
- ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,8968,1,4,0)
- ;;=4^C82.09
- ;;^UTILITY(U,$J,358.3,8968,2)
- ;;=^5001470
- ;;^UTILITY(U,$J,358.3,8969,0)
- ;;=C82.00^^45^431^70
- ;;^UTILITY(U,$J,358.3,8969,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8969,1,3,0)
- ;;=3^Follicular Lymphoma Grade I,Unspec Site
- ;;^UTILITY(U,$J,358.3,8969,1,4,0)
- ;;=4^C82.00
- ;;^UTILITY(U,$J,358.3,8969,2)
- ;;=^5001461
- ;;^UTILITY(U,$J,358.3,8970,0)
- ;;=C82.19^^45^431^71
- ;;^UTILITY(U,$J,358.3,8970,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8970,1,3,0)
- ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,8970,1,4,0)
- ;;=4^C82.19
- ;;^UTILITY(U,$J,358.3,8970,2)
- ;;=^5001480
- ;;^UTILITY(U,$J,358.3,8971,0)
- ;;=C82.10^^45^431^72
- ;;^UTILITY(U,$J,358.3,8971,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8971,1,3,0)
- ;;=3^Follicular Lymphoma Grade II,Unspec Site
- ;;^UTILITY(U,$J,358.3,8971,1,4,0)
- ;;=4^C82.10
- ;;^UTILITY(U,$J,358.3,8971,2)
- ;;=^5001471
- ;;^UTILITY(U,$J,358.3,8972,0)
- ;;=C82.29^^45^431^73
- ;;^UTILITY(U,$J,358.3,8972,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8972,1,3,0)
- ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,8972,1,4,0)
- ;;=4^C82.29
- ;;^UTILITY(U,$J,358.3,8972,2)
- ;;=^5001490
- ;;^UTILITY(U,$J,358.3,8973,0)
- ;;=C82.20^^45^431^74
- ;;^UTILITY(U,$J,358.3,8973,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8973,1,3,0)
- ;;=3^Follicular Lymphoma Grade III,Unspec Site
- ;;^UTILITY(U,$J,358.3,8973,1,4,0)
- ;;=4^C82.20
- ;;^UTILITY(U,$J,358.3,8973,2)
- ;;=^5001481
- ;;^UTILITY(U,$J,358.3,8974,0)
- ;;=C82.39^^45^431^75
- ;;^UTILITY(U,$J,358.3,8974,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8974,1,3,0)
- ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,8974,1,4,0)
- ;;=4^C82.39
- ;;^UTILITY(U,$J,358.3,8974,2)
- ;;=^5001500
- ;;^UTILITY(U,$J,358.3,8975,0)
- ;;=C82.30^^45^431^76
- ;;^UTILITY(U,$J,358.3,8975,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8975,1,3,0)
- ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
- ;;^UTILITY(U,$J,358.3,8975,1,4,0)
- ;;=4^C82.30
- ;;^UTILITY(U,$J,358.3,8975,2)
- ;;=^5001491
- ;;^UTILITY(U,$J,358.3,8976,0)
- ;;=C82.49^^45^431^77
- ;;^UTILITY(U,$J,358.3,8976,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8976,1,3,0)
- ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,8976,1,4,0)
- ;;=4^C82.49
- ;;^UTILITY(U,$J,358.3,8976,2)
- ;;=^5001510
- ;;^UTILITY(U,$J,358.3,8977,0)
- ;;=C82.40^^45^431^78
- ;;^UTILITY(U,$J,358.3,8977,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8977,1,3,0)
- ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
- ;;^UTILITY(U,$J,358.3,8977,1,4,0)
- ;;=4^C82.40
- ;;^UTILITY(U,$J,358.3,8977,2)
- ;;=^5001501
- ;;^UTILITY(U,$J,358.3,8978,0)
- ;;=C82.99^^45^431^79
- ;;^UTILITY(U,$J,358.3,8978,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8978,1,3,0)
- ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,8978,1,4,0)
- ;;=4^C82.99
- ;;^UTILITY(U,$J,358.3,8978,2)
- ;;=^5001550
- ;;^UTILITY(U,$J,358.3,8979,0)
- ;;=C82.90^^45^431^80
- ;;^UTILITY(U,$J,358.3,8979,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8979,1,3,0)
- ;;=3^Follicular Lymphoma Unspec,Unspec Site
- ;;^UTILITY(U,$J,358.3,8979,1,4,0)
- ;;=4^C82.90
- ;;^UTILITY(U,$J,358.3,8979,2)
- ;;=^5001541
- ;;^UTILITY(U,$J,358.3,8980,0)
- ;;=R59.1^^45^431^65
- ;;^UTILITY(U,$J,358.3,8980,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8980,1,3,0)
- ;;=3^Enlarged Lymph Nodes,Generalized
- ;;^UTILITY(U,$J,358.3,8980,1,4,0)
- ;;=4^R59.1
- ;;^UTILITY(U,$J,358.3,8980,2)
- ;;=^5019530
- ;;^UTILITY(U,$J,358.3,8981,0)
- ;;=C91.40^^45^431^84
- ;;^UTILITY(U,$J,358.3,8981,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8981,1,3,0)
- ;;=3^Hairy Cell Leukemia,Not in Remission
- ;;^UTILITY(U,$J,358.3,8981,1,4,0)
- ;;=4^C91.40
- ;;^UTILITY(U,$J,358.3,8981,2)
- ;;=^5001771
- ;;^UTILITY(U,$J,358.3,8982,0)
- ;;=C91.42^^45^431^82
- ;;^UTILITY(U,$J,358.3,8982,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8982,1,3,0)
- ;;=3^Hairy Cell Leukemia,In Relapse
- ;;^UTILITY(U,$J,358.3,8982,1,4,0)
- ;;=4^C91.42
- ;;^UTILITY(U,$J,358.3,8982,2)
- ;;=^5001773
- ;;^UTILITY(U,$J,358.3,8983,0)
- ;;=C91.41^^45^431^83
- ;;^UTILITY(U,$J,358.3,8983,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8983,1,3,0)
- ;;=3^Hairy Cell Leukemia,In Remission
- ;;^UTILITY(U,$J,358.3,8983,1,4,0)
- ;;=4^C91.41
- ;;^UTILITY(U,$J,358.3,8983,2)
- ;;=^5001772
- ;;^UTILITY(U,$J,358.3,8984,0)
- ;;=D57.01^^45^431^85
- ;;^UTILITY(U,$J,358.3,8984,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8984,1,3,0)
- ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
- ;;^UTILITY(U,$J,358.3,8984,1,4,0)
- ;;=4^D57.01
- ;;^UTILITY(U,$J,358.3,8984,2)
- ;;=^5002307
- ;;^UTILITY(U,$J,358.3,8985,0)
- ;;=D57.00^^45^431^86
- ;;^UTILITY(U,$J,358.3,8985,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8985,1,3,0)
- ;;=3^Hb-SS Disease w/ Crisis,Unspec
- ;;^UTILITY(U,$J,358.3,8985,1,4,0)
- ;;=4^D57.00
- ;;^UTILITY(U,$J,358.3,8985,2)
- ;;=^5002306
- ;;^UTILITY(U,$J,358.3,8986,0)
- ;;=D57.02^^45^431^87
- ;;^UTILITY(U,$J,358.3,8986,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8986,1,3,0)
- ;;=3^Hb-SS Disease w/ Splenic Sequestration
- ;;^UTILITY(U,$J,358.3,8986,1,4,0)
- ;;=4^D57.02
- ;;^UTILITY(U,$J,358.3,8986,2)
- ;;=^5002308
- ;;^UTILITY(U,$J,358.3,8987,0)
- ;;=D68.32^^45^431^89
- ;;^UTILITY(U,$J,358.3,8987,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8987,1,3,0)
- ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
- ;;^UTILITY(U,$J,358.3,8987,1,4,0)
- ;;=4^D68.32
- ;;^UTILITY(U,$J,358.3,8987,2)
- ;;=^5002357
- ;;^UTILITY(U,$J,358.3,8988,0)
- ;;=C22.2^^45^431^90
- ;;^UTILITY(U,$J,358.3,8988,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8988,1,3,0)
- ;;=3^Hepatoblastoma
- ;;^UTILITY(U,$J,358.3,8988,1,4,0)
- ;;=4^C22.2
- ;;^UTILITY(U,$J,358.3,8988,2)
- ;;=^5000935
- ;;^UTILITY(U,$J,358.3,8989,0)
- ;;=D58.9^^45^431^92
- ;;^UTILITY(U,$J,358.3,8989,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8989,1,3,0)
- ;;=3^Hereditary Hemolytic Anemia,Unspec
- ;;^UTILITY(U,$J,358.3,8989,1,4,0)
- ;;=4^D58.9
- ;;^UTILITY(U,$J,358.3,8989,2)
- ;;=^5002322
- ;;^UTILITY(U,$J,358.3,8990,0)
- ;;=C81.99^^45^431^93
- ;;^UTILITY(U,$J,358.3,8990,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8990,1,3,0)
- ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,8990,1,4,0)
- ;;=4^C81.99
- ;;^UTILITY(U,$J,358.3,8990,2)
- ;;=^5001460
- ;;^UTILITY(U,$J,358.3,8991,0)
- ;;=C81.90^^45^431^94
- ;;^UTILITY(U,$J,358.3,8991,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8991,1,3,0)
- ;;=3^Hodgkin Lymphoma,Unspec Site
- ;;^UTILITY(U,$J,358.3,8991,1,4,0)
- ;;=4^C81.90
- ;;^UTILITY(U,$J,358.3,8991,2)
- ;;=^5001451
- ;;^UTILITY(U,$J,358.3,8992,0)
- ;;=D89.2^^45^431^95
- ;;^UTILITY(U,$J,358.3,8992,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8992,1,3,0)
- ;;=3^Hypergammaglobulenemia,Unspec
- ;;^UTILITY(U,$J,358.3,8992,1,4,0)
- ;;=4^D89.2
- ;;^UTILITY(U,$J,358.3,8992,2)
- ;;=^5002455
- ;;^UTILITY(U,$J,358.3,8993,0)
- ;;=D05.12^^45^431^98
- ;;^UTILITY(U,$J,358.3,8993,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8993,1,3,0)
- ;;=3^Intraductal Carcinoma in Situ,Left Breast
- ;;^UTILITY(U,$J,358.3,8993,1,4,0)
- ;;=4^D05.12
- ;;^UTILITY(U,$J,358.3,8993,2)
- ;;=^5001931
- ;;^UTILITY(U,$J,358.3,8994,0)
- ;;=D05.11^^45^431^99
- ;;^UTILITY(U,$J,358.3,8994,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8994,1,3,0)
- ;;=3^Intraductal Carcinoma in Situ,Right Breast
- ;;^UTILITY(U,$J,358.3,8994,1,4,0)
- ;;=4^D05.11
- ;;^UTILITY(U,$J,358.3,8994,2)
- ;;=^5001930
- ;;^UTILITY(U,$J,358.3,8995,0)
- ;;=D05.10^^45^431^100
- ;;^UTILITY(U,$J,358.3,8995,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8995,1,3,0)
- ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
- ;;^UTILITY(U,$J,358.3,8995,1,4,0)
- ;;=4^D05.10
- ;;^UTILITY(U,$J,358.3,8995,2)
- ;;=^5001929
- ;;^UTILITY(U,$J,358.3,8996,0)
- ;;=D50.0^^45^431^101
- ;;^UTILITY(U,$J,358.3,8996,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8996,1,3,0)
- ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
- ;;^UTILITY(U,$J,358.3,8996,1,4,0)
- ;;=4^D50.0
- ;;^UTILITY(U,$J,358.3,8996,2)
- ;;=^267971
- ;;^UTILITY(U,$J,358.3,8997,0)
- ;;=D50.9^^45^431^102
- ;;^UTILITY(U,$J,358.3,8997,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8997,1,3,0)
- ;;=3^Iron Deficiency Anemia,Unspec
- ;;^UTILITY(U,$J,358.3,8997,1,4,0)
- ;;=4^D50.9
- ;;^UTILITY(U,$J,358.3,8997,2)
- ;;=^5002283
- ;;^UTILITY(U,$J,358.3,8998,0)
- ;;=C46.9^^45^431^103
- ;;^UTILITY(U,$J,358.3,8998,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8998,1,3,0)
- ;;=3^Kaposi's Sarcoma,Unspec
- ;;^UTILITY(U,$J,358.3,8998,1,4,0)
- ;;=4^C46.9
- ;;^UTILITY(U,$J,358.3,8998,2)
- ;;=^5001108
- ;;^UTILITY(U,$J,358.3,8999,0)
- ;;=C22.0^^45^431^104
- ;;^UTILITY(U,$J,358.3,8999,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8999,1,3,0)
- ;;=3^Liver Cell Carcinoma
- ;;^UTILITY(U,$J,358.3,8999,1,4,0)
- ;;=4^C22.0
- ;;^UTILITY(U,$J,358.3,8999,2)
- ;;=^5000933
- ;;^UTILITY(U,$J,358.3,9000,0)
- ;;=D05.02^^45^431^105
- ;;^UTILITY(U,$J,358.3,9000,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,9000,1,3,0)
- ;;=3^Lobular Carcinoma in Situ,Left Breast
- ;;^UTILITY(U,$J,358.3,9000,1,4,0)
- ;;=4^D05.02
- ;;^UTILITY(U,$J,358.3,9000,2)
- ;;=^5001928
- ;;^UTILITY(U,$J,358.3,9001,0)
- ;;=D05.01^^45^431^106
- ;;^UTILITY(U,$J,358.3,9001,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,9001,1,3,0)
- ;;=3^Lobular Carcinoma in Situ,Right Breast
- ;;^UTILITY(U,$J,358.3,9001,1,4,0)
- ;;=4^D05.01
- ;;^UTILITY(U,$J,358.3,9001,2)
- ;;=^5001927
- ;;^UTILITY(U,$J,358.3,9002,0)
- ;;=D05.00^^45^431^107
- ;;^UTILITY(U,$J,358.3,9002,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,9002,1,3,0)
- ;;=3^Lobular Carcinoma in Situ,Unspec Breast
- ;;^UTILITY(U,$J,358.3,9002,1,4,0)
- ;;=4^D05.00
- ;;^UTILITY(U,$J,358.3,9002,2)
- ;;=^5001926
- ;;^UTILITY(U,$J,358.3,9003,0)
- ;;=R59.0^^45^431^66
- ;;^UTILITY(U,$J,358.3,9003,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,9003,1,3,0)
- ;;=3^Enlarged Lymph Nodes,Localized
- ;;^UTILITY(U,$J,358.3,9003,1,4,0)
- ;;=4^R59.0
- ;;^UTILITY(U,$J,358.3,9003,2)
- ;;=^5019529
- ;;^UTILITY(U,$J,358.3,9004,0)
- ;;=C83.59^^45^431^108
- ;;^UTILITY(U,$J,358.3,9004,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,9004,1,3,0)
- ;;=3^Lymphoblastic Lymphoma,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,9004,1,4,0)
- ;;=4^C83.59
- ;;^UTILITY(U,$J,358.3,9004,2)
- ;;=^5001590
- ;;^UTILITY(U,$J,358.3,9005,0)
- ;;=C83.50^^45^431^109
- ;;^UTILITY(U,$J,358.3,9005,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,9005,1,3,0)
- ;;=3^Lymphoblastic Lymphoma,Unspec Site
- ;;^UTILITY(U,$J,358.3,9005,1,4,0)
- ;;=4^C83.50
- ;;^UTILITY(U,$J,358.3,9005,2)
- ;;=^5001581
- ;;^UTILITY(U,$J,358.3,9006,0)
- ;;=C43.9^^45^431^112
- ;;^UTILITY(U,$J,358.3,9006,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,9006,1,3,0)
- ;;=3^Malig Melanoma of Skin,Unspec Site
- ;;^UTILITY(U,$J,358.3,9006,1,4,0)
- ;;=4^C43.9
- ;;^UTILITY(U,$J,358.3,9006,2)
- ;;=^5001015
- ;;^UTILITY(U,$J,358.3,9007,0)
- ;;=C31.9^^45^431^113
- ;;^UTILITY(U,$J,358.3,9007,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,9007,1,3,0)
- ;;=3^Malig Neop Accessory Sinus,Unspec
- ;;^UTILITY(U,$J,358.3,9007,1,4,0)
- ;;=4^C31.9
- ;;^UTILITY(U,$J,358.3,9007,2)
- ;;=^5000953
- ;;^UTILITY(U,$J,358.3,9008,0)
- ;;=C24.1^^45^431^115
- ;;^UTILITY(U,$J,358.3,9008,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,9008,1,3,0)
- ;;=3^Malig Neop Ampulla of Vater
- ;;^UTILITY(U,$J,358.3,9008,1,4,0)
- ;;=4^C24.1
- ;;^UTILITY(U,$J,358.3,9008,2)
- ;;=^267100
- ;;^UTILITY(U,$J,358.3,9009,0)
- ;;=C21.0^^45^431^116
- ;;^UTILITY(U,$J,358.3,9009,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,9009,1,3,0)
- ;;=3^Malig Neop Anus,Unspec
- ;;^UTILITY(U,$J,358.3,9009,1,4,0)
- ;;=4^C21.0
- ;;^UTILITY(U,$J,358.3,9009,2)
- ;;=^5000930
- ;;^UTILITY(U,$J,358.3,9010,0)
- ;;=C67.9^^45^431^119
- ;;^UTILITY(U,$J,358.3,9010,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,9010,1,3,0)
- ;;=3^Malig Neop Bladder,Unspec
- ;;^UTILITY(U,$J,358.3,9010,1,4,0)
- ;;=4^C67.9
- ;;^UTILITY(U,$J,358.3,9010,2)
- ;;=^5001263
- ;;^UTILITY(U,$J,358.3,9011,0)
- ;;=C71.9^^45^431^123
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI03Q 19794 printed Feb 18, 2025@23:07:25 Page 2
- IBDEI03Q ; ; 01-AUG-2022
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,8942,1,4,0)
- +2 ;;=4^D63.0
- +3 ;;^UTILITY(U,$J,358.3,8942,2)
- +4 ;;=^321978
- +5 ;;^UTILITY(U,$J,358.3,8943,0)
- +6 ;;=D63.8^^45^431^22
- +7 ;;^UTILITY(U,$J,358.3,8943,1,0)
- +8 ;;=^358.31IA^4^2
- +9 ;;^UTILITY(U,$J,358.3,8943,1,3,0)
- +10 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
- +11 ;;^UTILITY(U,$J,358.3,8943,1,4,0)
- +12 ;;=4^D63.8
- +13 ;;^UTILITY(U,$J,358.3,8943,2)
- +14 ;;=^5002343
- +15 ;;^UTILITY(U,$J,358.3,8944,0)
- +16 ;;=C22.3^^45^431^27
- +17 ;;^UTILITY(U,$J,358.3,8944,1,0)
- +18 ;;=^358.31IA^4^2
- +19 ;;^UTILITY(U,$J,358.3,8944,1,3,0)
- +20 ;;=3^Angiosarcoma of Liver
- +21 ;;^UTILITY(U,$J,358.3,8944,1,4,0)
- +22 ;;=4^C22.3
- +23 ;;^UTILITY(U,$J,358.3,8944,2)
- +24 ;;=^5000936
- +25 ;;^UTILITY(U,$J,358.3,8945,0)
- +26 ;;=D61.9^^45^431^28
- +27 ;;^UTILITY(U,$J,358.3,8945,1,0)
- +28 ;;=^358.31IA^4^2
- +29 ;;^UTILITY(U,$J,358.3,8945,1,3,0)
- +30 ;;=3^Aplastic Anemia,Unspec
- +31 ;;^UTILITY(U,$J,358.3,8945,1,4,0)
- +32 ;;=4^D61.9
- +33 ;;^UTILITY(U,$J,358.3,8945,2)
- +34 ;;=^5002342
- +35 ;;^UTILITY(U,$J,358.3,8946,0)
- +36 ;;=D56.1^^45^431^34
- +37 ;;^UTILITY(U,$J,358.3,8946,1,0)
- +38 ;;=^358.31IA^4^2
- +39 ;;^UTILITY(U,$J,358.3,8946,1,3,0)
- +40 ;;=3^Beta Thalassemia
- +41 ;;^UTILITY(U,$J,358.3,8946,1,4,0)
- +42 ;;=4^D56.1
- +43 ;;^UTILITY(U,$J,358.3,8946,2)
- +44 ;;=^340495
- +45 ;;^UTILITY(U,$J,358.3,8947,0)
- +46 ;;=C83.79^^45^431^36
- +47 ;;^UTILITY(U,$J,358.3,8947,1,0)
- +48 ;;=^358.31IA^4^2
- +49 ;;^UTILITY(U,$J,358.3,8947,1,3,0)
- +50 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
- +51 ;;^UTILITY(U,$J,358.3,8947,1,4,0)
- +52 ;;=4^C83.79
- +53 ;;^UTILITY(U,$J,358.3,8947,2)
- +54 ;;=^5001600
- +55 ;;^UTILITY(U,$J,358.3,8948,0)
- +56 ;;=C83.70^^45^431^37
- +57 ;;^UTILITY(U,$J,358.3,8948,1,0)
- +58 ;;=^358.31IA^4^2
- +59 ;;^UTILITY(U,$J,358.3,8948,1,3,0)
- +60 ;;=3^Burkitt Lymphoma,Unspec Site
- +61 ;;^UTILITY(U,$J,358.3,8948,1,4,0)
- +62 ;;=4^C83.70
- +63 ;;^UTILITY(U,$J,358.3,8948,2)
- +64 ;;=^5001591
- +65 ;;^UTILITY(U,$J,358.3,8949,0)
- +66 ;;=D09.0^^45^431^44
- +67 ;;^UTILITY(U,$J,358.3,8949,1,0)
- +68 ;;=^358.31IA^4^2
- +69 ;;^UTILITY(U,$J,358.3,8949,1,3,0)
- +70 ;;=3^Carcinoma in Situ of Bladder
- +71 ;;^UTILITY(U,$J,358.3,8949,1,4,0)
- +72 ;;=4^D09.0
- +73 ;;^UTILITY(U,$J,358.3,8949,2)
- +74 ;;=^267742
- +75 ;;^UTILITY(U,$J,358.3,8950,0)
- +76 ;;=D06.9^^45^431^45
- +77 ;;^UTILITY(U,$J,358.3,8950,1,0)
- +78 ;;=^358.31IA^4^2
- +79 ;;^UTILITY(U,$J,358.3,8950,1,3,0)
- +80 ;;=3^Carcinoma in Situ of Cervix
- +81 ;;^UTILITY(U,$J,358.3,8950,1,4,0)
- +82 ;;=4^D06.9
- +83 ;;^UTILITY(U,$J,358.3,8950,2)
- +84 ;;=^5001941
- +85 ;;^UTILITY(U,$J,358.3,8951,0)
- +86 ;;=D06.0^^45^431^47
- +87 ;;^UTILITY(U,$J,358.3,8951,1,0)
- +88 ;;=^358.31IA^4^2
- +89 ;;^UTILITY(U,$J,358.3,8951,1,3,0)
- +90 ;;=3^Carcinoma in Situ of Endocervix
- +91 ;;^UTILITY(U,$J,358.3,8951,1,4,0)
- +92 ;;=4^D06.0
- +93 ;;^UTILITY(U,$J,358.3,8951,2)
- +94 ;;=^5001938
- +95 ;;^UTILITY(U,$J,358.3,8952,0)
- +96 ;;=D06.1^^45^431^48
- +97 ;;^UTILITY(U,$J,358.3,8952,1,0)
- +98 ;;=^358.31IA^4^2
- +99 ;;^UTILITY(U,$J,358.3,8952,1,3,0)
- +100 ;;=3^Carcinoma in Situ of Exocervix
- +101 ;;^UTILITY(U,$J,358.3,8952,1,4,0)
- +102 ;;=4^D06.1
- +103 ;;^UTILITY(U,$J,358.3,8952,2)
- +104 ;;=^5001939
- +105 ;;^UTILITY(U,$J,358.3,8953,0)
- +106 ;;=D06.7^^45^431^46
- +107 ;;^UTILITY(U,$J,358.3,8953,1,0)
- +108 ;;=^358.31IA^4^2
- +109 ;;^UTILITY(U,$J,358.3,8953,1,3,0)
- +110 ;;=3^Carcinoma in Situ of Cervix,Other Parts
- +111 ;;^UTILITY(U,$J,358.3,8953,1,4,0)
- +112 ;;=4^D06.7
- +113 ;;^UTILITY(U,$J,358.3,8953,2)
- +114 ;;=^5001940
- +115 ;;^UTILITY(U,$J,358.3,8954,0)
- +116 ;;=D04.9^^45^431^49
- +117 ;;^UTILITY(U,$J,358.3,8954,1,0)
- +118 ;;=^358.31IA^4^2
- +119 ;;^UTILITY(U,$J,358.3,8954,1,3,0)
- +120 ;;=3^Carcinoma in Situ of Skin
- +121 ;;^UTILITY(U,$J,358.3,8954,1,4,0)
- +122 ;;=4^D04.9
- +123 ;;^UTILITY(U,$J,358.3,8954,2)
- +124 ;;=^5001925
- +125 ;;^UTILITY(U,$J,358.3,8955,0)
- +126 ;;=C91.11^^45^431^52
- +127 ;;^UTILITY(U,$J,358.3,8955,1,0)
- +128 ;;=^358.31IA^4^2
- +129 ;;^UTILITY(U,$J,358.3,8955,1,3,0)
- +130 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
- +131 ;;^UTILITY(U,$J,358.3,8955,1,4,0)
- +132 ;;=4^C91.11
- +133 ;;^UTILITY(U,$J,358.3,8955,2)
- +134 ;;=^5001766
- +135 ;;^UTILITY(U,$J,358.3,8956,0)
- +136 ;;=C91.10^^45^431^53
- +137 ;;^UTILITY(U,$J,358.3,8956,1,0)
- +138 ;;=^358.31IA^4^2
- +139 ;;^UTILITY(U,$J,358.3,8956,1,3,0)
- +140 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
- +141 ;;^UTILITY(U,$J,358.3,8956,1,4,0)
- +142 ;;=4^C91.10
- +143 ;;^UTILITY(U,$J,358.3,8956,2)
- +144 ;;=^5001765
- +145 ;;^UTILITY(U,$J,358.3,8957,0)
- +146 ;;=C92.11^^45^431^54
- +147 ;;^UTILITY(U,$J,358.3,8957,1,0)
- +148 ;;=^358.31IA^4^2
- +149 ;;^UTILITY(U,$J,358.3,8957,1,3,0)
- +150 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
- +151 ;;^UTILITY(U,$J,358.3,8957,1,4,0)
- +152 ;;=4^C92.11
- +153 ;;^UTILITY(U,$J,358.3,8957,2)
- +154 ;;=^5001793
- +155 ;;^UTILITY(U,$J,358.3,8958,0)
- +156 ;;=C92.10^^45^431^55
- +157 ;;^UTILITY(U,$J,358.3,8958,1,0)
- +158 ;;=^358.31IA^4^2
- +159 ;;^UTILITY(U,$J,358.3,8958,1,3,0)
- +160 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
- +161 ;;^UTILITY(U,$J,358.3,8958,1,4,0)
- +162 ;;=4^C92.10
- +163 ;;^UTILITY(U,$J,358.3,8958,2)
- +164 ;;=^5001792
- +165 ;;^UTILITY(U,$J,358.3,8959,0)
- +166 ;;=D47.1^^45^431^56
- +167 ;;^UTILITY(U,$J,358.3,8959,1,0)
- +168 ;;=^358.31IA^4^2
- +169 ;;^UTILITY(U,$J,358.3,8959,1,3,0)
- +170 ;;=3^Chronic Myeloproliferative Disease
- +171 ;;^UTILITY(U,$J,358.3,8959,1,4,0)
- +172 ;;=4^D47.1
- +173 ;;^UTILITY(U,$J,358.3,8959,2)
- +174 ;;=^5002256
- +175 ;;^UTILITY(U,$J,358.3,8960,0)
- +176 ;;=C82.69^^45^431^57
- +177 ;;^UTILITY(U,$J,358.3,8960,1,0)
- +178 ;;=^358.31IA^4^2
- +179 ;;^UTILITY(U,$J,358.3,8960,1,3,0)
- +180 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
- +181 ;;^UTILITY(U,$J,358.3,8960,1,4,0)
- +182 ;;=4^C82.69
- +183 ;;^UTILITY(U,$J,358.3,8960,2)
- +184 ;;=^5001530
- +185 ;;^UTILITY(U,$J,358.3,8961,0)
- +186 ;;=C82.60^^45^431^58
- +187 ;;^UTILITY(U,$J,358.3,8961,1,0)
- +188 ;;=^358.31IA^4^2
- +189 ;;^UTILITY(U,$J,358.3,8961,1,3,0)
- +190 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
- +191 ;;^UTILITY(U,$J,358.3,8961,1,4,0)
- +192 ;;=4^C82.60
- +193 ;;^UTILITY(U,$J,358.3,8961,2)
- +194 ;;=^5001521
- +195 ;;^UTILITY(U,$J,358.3,8962,0)
- +196 ;;=D56.2^^45^431^59
- +197 ;;^UTILITY(U,$J,358.3,8962,1,0)
- +198 ;;=^358.31IA^4^2
- +199 ;;^UTILITY(U,$J,358.3,8962,1,3,0)
- +200 ;;=3^Delta-Beta Thalassemia
- +201 ;;^UTILITY(U,$J,358.3,8962,1,4,0)
- +202 ;;=4^D56.2
- +203 ;;^UTILITY(U,$J,358.3,8962,2)
- +204 ;;=^340496
- +205 ;;^UTILITY(U,$J,358.3,8963,0)
- +206 ;;=D75.9^^45^431^60
- +207 ;;^UTILITY(U,$J,358.3,8963,1,0)
- +208 ;;=^358.31IA^4^2
- +209 ;;^UTILITY(U,$J,358.3,8963,1,3,0)
- +210 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
- +211 ;;^UTILITY(U,$J,358.3,8963,1,4,0)
- +212 ;;=4^D75.9
- +213 ;;^UTILITY(U,$J,358.3,8963,2)
- +214 ;;=^5002393
- +215 ;;^UTILITY(U,$J,358.3,8964,0)
- +216 ;;=D59.0^^45^431^63
- +217 ;;^UTILITY(U,$J,358.3,8964,1,0)
- +218 ;;=^358.31IA^4^2
- +219 ;;^UTILITY(U,$J,358.3,8964,1,3,0)
- +220 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
- +221 ;;^UTILITY(U,$J,358.3,8964,1,4,0)
- +222 ;;=4^D59.0
- +223 ;;^UTILITY(U,$J,358.3,8964,2)
- +224 ;;=^5002323
- +225 ;;^UTILITY(U,$J,358.3,8965,0)
- +226 ;;=D59.2^^45^431^64
- +227 ;;^UTILITY(U,$J,358.3,8965,1,0)
- +228 ;;=^358.31IA^4^2
- +229 ;;^UTILITY(U,$J,358.3,8965,1,3,0)
- +230 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
- +231 ;;^UTILITY(U,$J,358.3,8965,1,4,0)
- +232 ;;=4^D59.2
- +233 ;;^UTILITY(U,$J,358.3,8965,2)
- +234 ;;=^5002325
- +235 ;;^UTILITY(U,$J,358.3,8966,0)
- +236 ;;=R59.9^^45^431^67
- +237 ;;^UTILITY(U,$J,358.3,8966,1,0)
- +238 ;;=^358.31IA^4^2
- +239 ;;^UTILITY(U,$J,358.3,8966,1,3,0)
- +240 ;;=3^Enlarged Lymph Nodes,Unspec
- +241 ;;^UTILITY(U,$J,358.3,8966,1,4,0)
- +242 ;;=4^R59.9
- +243 ;;^UTILITY(U,$J,358.3,8966,2)
- +244 ;;=^5019531
- +245 ;;^UTILITY(U,$J,358.3,8967,0)
- +246 ;;=D47.3^^45^431^68
- +247 ;;^UTILITY(U,$J,358.3,8967,1,0)
- +248 ;;=^358.31IA^4^2
- +249 ;;^UTILITY(U,$J,358.3,8967,1,3,0)
- +250 ;;=3^Essential Thrombocythemia
- +251 ;;^UTILITY(U,$J,358.3,8967,1,4,0)
- +252 ;;=4^D47.3
- +253 ;;^UTILITY(U,$J,358.3,8967,2)
- +254 ;;=^5002258
- +255 ;;^UTILITY(U,$J,358.3,8968,0)
- +256 ;;=C82.09^^45^431^69
- +257 ;;^UTILITY(U,$J,358.3,8968,1,0)
- +258 ;;=^358.31IA^4^2
- +259 ;;^UTILITY(U,$J,358.3,8968,1,3,0)
- +260 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
- +261 ;;^UTILITY(U,$J,358.3,8968,1,4,0)
- +262 ;;=4^C82.09
- +263 ;;^UTILITY(U,$J,358.3,8968,2)
- +264 ;;=^5001470
- +265 ;;^UTILITY(U,$J,358.3,8969,0)
- +266 ;;=C82.00^^45^431^70
- +267 ;;^UTILITY(U,$J,358.3,8969,1,0)
- +268 ;;=^358.31IA^4^2
- +269 ;;^UTILITY(U,$J,358.3,8969,1,3,0)
- +270 ;;=3^Follicular Lymphoma Grade I,Unspec Site
- +271 ;;^UTILITY(U,$J,358.3,8969,1,4,0)
- +272 ;;=4^C82.00
- +273 ;;^UTILITY(U,$J,358.3,8969,2)
- +274 ;;=^5001461
- +275 ;;^UTILITY(U,$J,358.3,8970,0)
- +276 ;;=C82.19^^45^431^71
- +277 ;;^UTILITY(U,$J,358.3,8970,1,0)
- +278 ;;=^358.31IA^4^2
- +279 ;;^UTILITY(U,$J,358.3,8970,1,3,0)
- +280 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
- +281 ;;^UTILITY(U,$J,358.3,8970,1,4,0)
- +282 ;;=4^C82.19
- +283 ;;^UTILITY(U,$J,358.3,8970,2)
- +284 ;;=^5001480
- +285 ;;^UTILITY(U,$J,358.3,8971,0)
- +286 ;;=C82.10^^45^431^72
- +287 ;;^UTILITY(U,$J,358.3,8971,1,0)
- +288 ;;=^358.31IA^4^2
- +289 ;;^UTILITY(U,$J,358.3,8971,1,3,0)
- +290 ;;=3^Follicular Lymphoma Grade II,Unspec Site
- +291 ;;^UTILITY(U,$J,358.3,8971,1,4,0)
- +292 ;;=4^C82.10
- +293 ;;^UTILITY(U,$J,358.3,8971,2)
- +294 ;;=^5001471
- +295 ;;^UTILITY(U,$J,358.3,8972,0)
- +296 ;;=C82.29^^45^431^73
- +297 ;;^UTILITY(U,$J,358.3,8972,1,0)
- +298 ;;=^358.31IA^4^2
- +299 ;;^UTILITY(U,$J,358.3,8972,1,3,0)
- +300 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
- +301 ;;^UTILITY(U,$J,358.3,8972,1,4,0)
- +302 ;;=4^C82.29
- +303 ;;^UTILITY(U,$J,358.3,8972,2)
- +304 ;;=^5001490
- +305 ;;^UTILITY(U,$J,358.3,8973,0)
- +306 ;;=C82.20^^45^431^74
- +307 ;;^UTILITY(U,$J,358.3,8973,1,0)
- +308 ;;=^358.31IA^4^2
- +309 ;;^UTILITY(U,$J,358.3,8973,1,3,0)
- +310 ;;=3^Follicular Lymphoma Grade III,Unspec Site
- +311 ;;^UTILITY(U,$J,358.3,8973,1,4,0)
- +312 ;;=4^C82.20
- +313 ;;^UTILITY(U,$J,358.3,8973,2)
- +314 ;;=^5001481
- +315 ;;^UTILITY(U,$J,358.3,8974,0)
- +316 ;;=C82.39^^45^431^75
- +317 ;;^UTILITY(U,$J,358.3,8974,1,0)
- +318 ;;=^358.31IA^4^2
- +319 ;;^UTILITY(U,$J,358.3,8974,1,3,0)
- +320 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
- +321 ;;^UTILITY(U,$J,358.3,8974,1,4,0)
- +322 ;;=4^C82.39
- +323 ;;^UTILITY(U,$J,358.3,8974,2)
- +324 ;;=^5001500
- +325 ;;^UTILITY(U,$J,358.3,8975,0)
- +326 ;;=C82.30^^45^431^76
- +327 ;;^UTILITY(U,$J,358.3,8975,1,0)
- +328 ;;=^358.31IA^4^2
- +329 ;;^UTILITY(U,$J,358.3,8975,1,3,0)
- +330 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
- +331 ;;^UTILITY(U,$J,358.3,8975,1,4,0)
- +332 ;;=4^C82.30
- +333 ;;^UTILITY(U,$J,358.3,8975,2)
- +334 ;;=^5001491
- +335 ;;^UTILITY(U,$J,358.3,8976,0)
- +336 ;;=C82.49^^45^431^77
- +337 ;;^UTILITY(U,$J,358.3,8976,1,0)
- +338 ;;=^358.31IA^4^2
- +339 ;;^UTILITY(U,$J,358.3,8976,1,3,0)
- +340 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
- +341 ;;^UTILITY(U,$J,358.3,8976,1,4,0)
- +342 ;;=4^C82.49
- +343 ;;^UTILITY(U,$J,358.3,8976,2)
- +344 ;;=^5001510
- +345 ;;^UTILITY(U,$J,358.3,8977,0)
- +346 ;;=C82.40^^45^431^78
- +347 ;;^UTILITY(U,$J,358.3,8977,1,0)
- +348 ;;=^358.31IA^4^2
- +349 ;;^UTILITY(U,$J,358.3,8977,1,3,0)
- +350 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
- +351 ;;^UTILITY(U,$J,358.3,8977,1,4,0)
- +352 ;;=4^C82.40
- +353 ;;^UTILITY(U,$J,358.3,8977,2)
- +354 ;;=^5001501
- +355 ;;^UTILITY(U,$J,358.3,8978,0)
- +356 ;;=C82.99^^45^431^79
- +357 ;;^UTILITY(U,$J,358.3,8978,1,0)
- +358 ;;=^358.31IA^4^2
- +359 ;;^UTILITY(U,$J,358.3,8978,1,3,0)
- +360 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
- +361 ;;^UTILITY(U,$J,358.3,8978,1,4,0)
- +362 ;;=4^C82.99
- +363 ;;^UTILITY(U,$J,358.3,8978,2)
- +364 ;;=^5001550
- +365 ;;^UTILITY(U,$J,358.3,8979,0)
- +366 ;;=C82.90^^45^431^80
- +367 ;;^UTILITY(U,$J,358.3,8979,1,0)
- +368 ;;=^358.31IA^4^2
- +369 ;;^UTILITY(U,$J,358.3,8979,1,3,0)
- +370 ;;=3^Follicular Lymphoma Unspec,Unspec Site
- +371 ;;^UTILITY(U,$J,358.3,8979,1,4,0)
- +372 ;;=4^C82.90
- +373 ;;^UTILITY(U,$J,358.3,8979,2)
- +374 ;;=^5001541
- +375 ;;^UTILITY(U,$J,358.3,8980,0)
- +376 ;;=R59.1^^45^431^65
- +377 ;;^UTILITY(U,$J,358.3,8980,1,0)
- +378 ;;=^358.31IA^4^2
- +379 ;;^UTILITY(U,$J,358.3,8980,1,3,0)
- +380 ;;=3^Enlarged Lymph Nodes,Generalized
- +381 ;;^UTILITY(U,$J,358.3,8980,1,4,0)
- +382 ;;=4^R59.1
- +383 ;;^UTILITY(U,$J,358.3,8980,2)
- +384 ;;=^5019530
- +385 ;;^UTILITY(U,$J,358.3,8981,0)
- +386 ;;=C91.40^^45^431^84
- +387 ;;^UTILITY(U,$J,358.3,8981,1,0)
- +388 ;;=^358.31IA^4^2
- +389 ;;^UTILITY(U,$J,358.3,8981,1,3,0)
- +390 ;;=3^Hairy Cell Leukemia,Not in Remission
- +391 ;;^UTILITY(U,$J,358.3,8981,1,4,0)
- +392 ;;=4^C91.40
- +393 ;;^UTILITY(U,$J,358.3,8981,2)
- +394 ;;=^5001771
- +395 ;;^UTILITY(U,$J,358.3,8982,0)
- +396 ;;=C91.42^^45^431^82
- +397 ;;^UTILITY(U,$J,358.3,8982,1,0)
- +398 ;;=^358.31IA^4^2
- +399 ;;^UTILITY(U,$J,358.3,8982,1,3,0)
- +400 ;;=3^Hairy Cell Leukemia,In Relapse
- +401 ;;^UTILITY(U,$J,358.3,8982,1,4,0)
- +402 ;;=4^C91.42
- +403 ;;^UTILITY(U,$J,358.3,8982,2)
- +404 ;;=^5001773
- +405 ;;^UTILITY(U,$J,358.3,8983,0)
- +406 ;;=C91.41^^45^431^83
- +407 ;;^UTILITY(U,$J,358.3,8983,1,0)
- +408 ;;=^358.31IA^4^2
- +409 ;;^UTILITY(U,$J,358.3,8983,1,3,0)
- +410 ;;=3^Hairy Cell Leukemia,In Remission
- +411 ;;^UTILITY(U,$J,358.3,8983,1,4,0)
- +412 ;;=4^C91.41
- +413 ;;^UTILITY(U,$J,358.3,8983,2)
- +414 ;;=^5001772
- +415 ;;^UTILITY(U,$J,358.3,8984,0)
- +416 ;;=D57.01^^45^431^85
- +417 ;;^UTILITY(U,$J,358.3,8984,1,0)
- +418 ;;=^358.31IA^4^2
- +419 ;;^UTILITY(U,$J,358.3,8984,1,3,0)
- +420 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
- +421 ;;^UTILITY(U,$J,358.3,8984,1,4,0)
- +422 ;;=4^D57.01
- +423 ;;^UTILITY(U,$J,358.3,8984,2)
- +424 ;;=^5002307
- +425 ;;^UTILITY(U,$J,358.3,8985,0)
- +426 ;;=D57.00^^45^431^86
- +427 ;;^UTILITY(U,$J,358.3,8985,1,0)
- +428 ;;=^358.31IA^4^2
- +429 ;;^UTILITY(U,$J,358.3,8985,1,3,0)
- +430 ;;=3^Hb-SS Disease w/ Crisis,Unspec
- +431 ;;^UTILITY(U,$J,358.3,8985,1,4,0)
- +432 ;;=4^D57.00
- +433 ;;^UTILITY(U,$J,358.3,8985,2)
- +434 ;;=^5002306
- +435 ;;^UTILITY(U,$J,358.3,8986,0)
- +436 ;;=D57.02^^45^431^87
- +437 ;;^UTILITY(U,$J,358.3,8986,1,0)
- +438 ;;=^358.31IA^4^2
- +439 ;;^UTILITY(U,$J,358.3,8986,1,3,0)
- +440 ;;=3^Hb-SS Disease w/ Splenic Sequestration
- +441 ;;^UTILITY(U,$J,358.3,8986,1,4,0)
- +442 ;;=4^D57.02
- +443 ;;^UTILITY(U,$J,358.3,8986,2)
- +444 ;;=^5002308
- +445 ;;^UTILITY(U,$J,358.3,8987,0)
- +446 ;;=D68.32^^45^431^89
- +447 ;;^UTILITY(U,$J,358.3,8987,1,0)
- +448 ;;=^358.31IA^4^2
- +449 ;;^UTILITY(U,$J,358.3,8987,1,3,0)
- +450 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
- +451 ;;^UTILITY(U,$J,358.3,8987,1,4,0)
- +452 ;;=4^D68.32
- +453 ;;^UTILITY(U,$J,358.3,8987,2)
- +454 ;;=^5002357
- +455 ;;^UTILITY(U,$J,358.3,8988,0)
- +456 ;;=C22.2^^45^431^90
- +457 ;;^UTILITY(U,$J,358.3,8988,1,0)
- +458 ;;=^358.31IA^4^2
- +459 ;;^UTILITY(U,$J,358.3,8988,1,3,0)
- +460 ;;=3^Hepatoblastoma
- +461 ;;^UTILITY(U,$J,358.3,8988,1,4,0)
- +462 ;;=4^C22.2
- +463 ;;^UTILITY(U,$J,358.3,8988,2)
- +464 ;;=^5000935
- +465 ;;^UTILITY(U,$J,358.3,8989,0)
- +466 ;;=D58.9^^45^431^92
- +467 ;;^UTILITY(U,$J,358.3,8989,1,0)
- +468 ;;=^358.31IA^4^2
- +469 ;;^UTILITY(U,$J,358.3,8989,1,3,0)
- +470 ;;=3^Hereditary Hemolytic Anemia,Unspec
- +471 ;;^UTILITY(U,$J,358.3,8989,1,4,0)
- +472 ;;=4^D58.9
- +473 ;;^UTILITY(U,$J,358.3,8989,2)
- +474 ;;=^5002322
- +475 ;;^UTILITY(U,$J,358.3,8990,0)
- +476 ;;=C81.99^^45^431^93
- +477 ;;^UTILITY(U,$J,358.3,8990,1,0)
- +478 ;;=^358.31IA^4^2
- +479 ;;^UTILITY(U,$J,358.3,8990,1,3,0)
- +480 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
- +481 ;;^UTILITY(U,$J,358.3,8990,1,4,0)
- +482 ;;=4^C81.99
- +483 ;;^UTILITY(U,$J,358.3,8990,2)
- +484 ;;=^5001460
- +485 ;;^UTILITY(U,$J,358.3,8991,0)
- +486 ;;=C81.90^^45^431^94
- +487 ;;^UTILITY(U,$J,358.3,8991,1,0)
- +488 ;;=^358.31IA^4^2
- +489 ;;^UTILITY(U,$J,358.3,8991,1,3,0)
- +490 ;;=3^Hodgkin Lymphoma,Unspec Site
- +491 ;;^UTILITY(U,$J,358.3,8991,1,4,0)
- +492 ;;=4^C81.90
- +493 ;;^UTILITY(U,$J,358.3,8991,2)
- +494 ;;=^5001451
- +495 ;;^UTILITY(U,$J,358.3,8992,0)
- +496 ;;=D89.2^^45^431^95
- +497 ;;^UTILITY(U,$J,358.3,8992,1,0)
- +498 ;;=^358.31IA^4^2
- +499 ;;^UTILITY(U,$J,358.3,8992,1,3,0)
- +500 ;;=3^Hypergammaglobulenemia,Unspec
- +501 ;;^UTILITY(U,$J,358.3,8992,1,4,0)
- +502 ;;=4^D89.2
- +503 ;;^UTILITY(U,$J,358.3,8992,2)
- +504 ;;=^5002455
- +505 ;;^UTILITY(U,$J,358.3,8993,0)
- +506 ;;=D05.12^^45^431^98
- +507 ;;^UTILITY(U,$J,358.3,8993,1,0)
- +508 ;;=^358.31IA^4^2
- +509 ;;^UTILITY(U,$J,358.3,8993,1,3,0)
- +510 ;;=3^Intraductal Carcinoma in Situ,Left Breast
- +511 ;;^UTILITY(U,$J,358.3,8993,1,4,0)
- +512 ;;=4^D05.12
- +513 ;;^UTILITY(U,$J,358.3,8993,2)
- +514 ;;=^5001931
- +515 ;;^UTILITY(U,$J,358.3,8994,0)
- +516 ;;=D05.11^^45^431^99
- +517 ;;^UTILITY(U,$J,358.3,8994,1,0)
- +518 ;;=^358.31IA^4^2
- +519 ;;^UTILITY(U,$J,358.3,8994,1,3,0)
- +520 ;;=3^Intraductal Carcinoma in Situ,Right Breast
- +521 ;;^UTILITY(U,$J,358.3,8994,1,4,0)
- +522 ;;=4^D05.11
- +523 ;;^UTILITY(U,$J,358.3,8994,2)
- +524 ;;=^5001930
- +525 ;;^UTILITY(U,$J,358.3,8995,0)
- +526 ;;=D05.10^^45^431^100
- +527 ;;^UTILITY(U,$J,358.3,8995,1,0)
- +528 ;;=^358.31IA^4^2
- +529 ;;^UTILITY(U,$J,358.3,8995,1,3,0)
- +530 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
- +531 ;;^UTILITY(U,$J,358.3,8995,1,4,0)
- +532 ;;=4^D05.10
- +533 ;;^UTILITY(U,$J,358.3,8995,2)
- +534 ;;=^5001929
- +535 ;;^UTILITY(U,$J,358.3,8996,0)
- +536 ;;=D50.0^^45^431^101
- +537 ;;^UTILITY(U,$J,358.3,8996,1,0)
- +538 ;;=^358.31IA^4^2
- +539 ;;^UTILITY(U,$J,358.3,8996,1,3,0)
- +540 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
- +541 ;;^UTILITY(U,$J,358.3,8996,1,4,0)
- +542 ;;=4^D50.0
- +543 ;;^UTILITY(U,$J,358.3,8996,2)
- +544 ;;=^267971
- +545 ;;^UTILITY(U,$J,358.3,8997,0)
- +546 ;;=D50.9^^45^431^102
- +547 ;;^UTILITY(U,$J,358.3,8997,1,0)
- +548 ;;=^358.31IA^4^2
- +549 ;;^UTILITY(U,$J,358.3,8997,1,3,0)
- +550 ;;=3^Iron Deficiency Anemia,Unspec
- +551 ;;^UTILITY(U,$J,358.3,8997,1,4,0)
- +552 ;;=4^D50.9
- +553 ;;^UTILITY(U,$J,358.3,8997,2)
- +554 ;;=^5002283
- +555 ;;^UTILITY(U,$J,358.3,8998,0)
- +556 ;;=C46.9^^45^431^103
- +557 ;;^UTILITY(U,$J,358.3,8998,1,0)
- +558 ;;=^358.31IA^4^2
- +559 ;;^UTILITY(U,$J,358.3,8998,1,3,0)
- +560 ;;=3^Kaposi's Sarcoma,Unspec
- +561 ;;^UTILITY(U,$J,358.3,8998,1,4,0)
- +562 ;;=4^C46.9
- +563 ;;^UTILITY(U,$J,358.3,8998,2)
- +564 ;;=^5001108
- +565 ;;^UTILITY(U,$J,358.3,8999,0)
- +566 ;;=C22.0^^45^431^104
- +567 ;;^UTILITY(U,$J,358.3,8999,1,0)
- +568 ;;=^358.31IA^4^2
- +569 ;;^UTILITY(U,$J,358.3,8999,1,3,0)
- +570 ;;=3^Liver Cell Carcinoma
- +571 ;;^UTILITY(U,$J,358.3,8999,1,4,0)
- +572 ;;=4^C22.0
- +573 ;;^UTILITY(U,$J,358.3,8999,2)
- +574 ;;=^5000933
- +575 ;;^UTILITY(U,$J,358.3,9000,0)
- +576 ;;=D05.02^^45^431^105
- +577 ;;^UTILITY(U,$J,358.3,9000,1,0)
- +578 ;;=^358.31IA^4^2
- +579 ;;^UTILITY(U,$J,358.3,9000,1,3,0)
- +580 ;;=3^Lobular Carcinoma in Situ,Left Breast
- +581 ;;^UTILITY(U,$J,358.3,9000,1,4,0)
- +582 ;;=4^D05.02
- +583 ;;^UTILITY(U,$J,358.3,9000,2)
- +584 ;;=^5001928
- +585 ;;^UTILITY(U,$J,358.3,9001,0)
- +586 ;;=D05.01^^45^431^106
- +587 ;;^UTILITY(U,$J,358.3,9001,1,0)
- +588 ;;=^358.31IA^4^2
- +589 ;;^UTILITY(U,$J,358.3,9001,1,3,0)
- +590 ;;=3^Lobular Carcinoma in Situ,Right Breast
- +591 ;;^UTILITY(U,$J,358.3,9001,1,4,0)
- +592 ;;=4^D05.01
- +593 ;;^UTILITY(U,$J,358.3,9001,2)
- +594 ;;=^5001927
- +595 ;;^UTILITY(U,$J,358.3,9002,0)
- +596 ;;=D05.00^^45^431^107
- +597 ;;^UTILITY(U,$J,358.3,9002,1,0)
- +598 ;;=^358.31IA^4^2
- +599 ;;^UTILITY(U,$J,358.3,9002,1,3,0)
- +600 ;;=3^Lobular Carcinoma in Situ,Unspec Breast
- +601 ;;^UTILITY(U,$J,358.3,9002,1,4,0)
- +602 ;;=4^D05.00
- +603 ;;^UTILITY(U,$J,358.3,9002,2)
- +604 ;;=^5001926
- +605 ;;^UTILITY(U,$J,358.3,9003,0)
- +606 ;;=R59.0^^45^431^66
- +607 ;;^UTILITY(U,$J,358.3,9003,1,0)
- +608 ;;=^358.31IA^4^2
- +609 ;;^UTILITY(U,$J,358.3,9003,1,3,0)
- +610 ;;=3^Enlarged Lymph Nodes,Localized
- +611 ;;^UTILITY(U,$J,358.3,9003,1,4,0)
- +612 ;;=4^R59.0
- +613 ;;^UTILITY(U,$J,358.3,9003,2)
- +614 ;;=^5019529
- +615 ;;^UTILITY(U,$J,358.3,9004,0)
- +616 ;;=C83.59^^45^431^108
- +617 ;;^UTILITY(U,$J,358.3,9004,1,0)
- +618 ;;=^358.31IA^4^2
- +619 ;;^UTILITY(U,$J,358.3,9004,1,3,0)
- +620 ;;=3^Lymphoblastic Lymphoma,Extranodal/Solid Organ Sites
- +621 ;;^UTILITY(U,$J,358.3,9004,1,4,0)
- +622 ;;=4^C83.59
- +623 ;;^UTILITY(U,$J,358.3,9004,2)
- +624 ;;=^5001590
- +625 ;;^UTILITY(U,$J,358.3,9005,0)
- +626 ;;=C83.50^^45^431^109
- +627 ;;^UTILITY(U,$J,358.3,9005,1,0)
- +628 ;;=^358.31IA^4^2
- +629 ;;^UTILITY(U,$J,358.3,9005,1,3,0)
- +630 ;;=3^Lymphoblastic Lymphoma,Unspec Site
- +631 ;;^UTILITY(U,$J,358.3,9005,1,4,0)
- +632 ;;=4^C83.50
- +633 ;;^UTILITY(U,$J,358.3,9005,2)
- +634 ;;=^5001581
- +635 ;;^UTILITY(U,$J,358.3,9006,0)
- +636 ;;=C43.9^^45^431^112
- +637 ;;^UTILITY(U,$J,358.3,9006,1,0)
- +638 ;;=^358.31IA^4^2
- +639 ;;^UTILITY(U,$J,358.3,9006,1,3,0)
- +640 ;;=3^Malig Melanoma of Skin,Unspec Site
- +641 ;;^UTILITY(U,$J,358.3,9006,1,4,0)
- +642 ;;=4^C43.9
- +643 ;;^UTILITY(U,$J,358.3,9006,2)
- +644 ;;=^5001015
- +645 ;;^UTILITY(U,$J,358.3,9007,0)
- +646 ;;=C31.9^^45^431^113
- +647 ;;^UTILITY(U,$J,358.3,9007,1,0)
- +648 ;;=^358.31IA^4^2
- +649 ;;^UTILITY(U,$J,358.3,9007,1,3,0)
- +650 ;;=3^Malig Neop Accessory Sinus,Unspec
- +651 ;;^UTILITY(U,$J,358.3,9007,1,4,0)
- +652 ;;=4^C31.9
- +653 ;;^UTILITY(U,$J,358.3,9007,2)
- +654 ;;=^5000953
- +655 ;;^UTILITY(U,$J,358.3,9008,0)
- +656 ;;=C24.1^^45^431^115
- +657 ;;^UTILITY(U,$J,358.3,9008,1,0)
- +658 ;;=^358.31IA^4^2
- +659 ;;^UTILITY(U,$J,358.3,9008,1,3,0)
- +660 ;;=3^Malig Neop Ampulla of Vater
- +661 ;;^UTILITY(U,$J,358.3,9008,1,4,0)
- +662 ;;=4^C24.1
- +663 ;;^UTILITY(U,$J,358.3,9008,2)
- +664 ;;=^267100
- +665 ;;^UTILITY(U,$J,358.3,9009,0)
- +666 ;;=C21.0^^45^431^116
- +667 ;;^UTILITY(U,$J,358.3,9009,1,0)
- +668 ;;=^358.31IA^4^2
- +669 ;;^UTILITY(U,$J,358.3,9009,1,3,0)
- +670 ;;=3^Malig Neop Anus,Unspec
- +671 ;;^UTILITY(U,$J,358.3,9009,1,4,0)
- +672 ;;=4^C21.0
- +673 ;;^UTILITY(U,$J,358.3,9009,2)
- +674 ;;=^5000930
- +675 ;;^UTILITY(U,$J,358.3,9010,0)
- +676 ;;=C67.9^^45^431^119
- +677 ;;^UTILITY(U,$J,358.3,9010,1,0)
- +678 ;;=^358.31IA^4^2
- +679 ;;^UTILITY(U,$J,358.3,9010,1,3,0)
- +680 ;;=3^Malig Neop Bladder,Unspec
- +681 ;;^UTILITY(U,$J,358.3,9010,1,4,0)
- +682 ;;=4^C67.9
- +683 ;;^UTILITY(U,$J,358.3,9010,2)
- +684 ;;=^5001263
- +685 ;;^UTILITY(U,$J,358.3,9011,0)
- +686 ;;=C71.9^^45^431^123